Jane S. Ricciuti, RPh, MS

Disclosures

September 20, 2002

In This Article

Antiviral Agents

Agenerase
(amprenavir) Capsule and Solution

Manufacturer: GlaxoSmithKline

Drug Approval Classification: Labeling Supplement to Original New Drug Application (Approval Date: 8/02/02)

New Drug Interactions: The labeling for Agenerase has been changed to include:

  • Patients taking Agenerase should be instructed not to use hormonal contraceptives because some birth control pills (those containing ethinyl estradiol/norethindrone) have been found to decrease the concentration of amprenavir. Therefore, patients receiving hormonal contraceptives should be instructed to use alternate contraceptive measures during therapy with amprenavir.

  • Coadministration of Agenerase and methadone can decrease plasma levels of methadone.

Agenerase (amprenavir) Labeling

Agenerase (amprenavir)

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....